Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3831281 Target Snapshot

P2X2/P2X3 heterotrimeric receptor · PROTEIN COMPLEX · Homo sapiens

951Compounds
39Assays
2Approved Drugs
1,273.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9UBL9. Use UniProt Q9UBL9 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UBL9 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats P2X2/P2X3 heterotrimeric receptor as ChEMBL target CHEMBL3831281, mapped to UniProt Q9UBL9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
P2X2/P2X3 heterotrimeric receptor
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3831281
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UBL9
P2X purinoceptor 2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether P2X2/P2X3 heterotrimeric receptor is the right protein anchor across sources, using UniProt Q9UBL9 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelP2X purinoceptor 2
UniProt AccessionQ9UBL9
Component TypeProtein
Sequence Length471 aa

P2X purinoceptor 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as P2X2/P2X3 heterotrimeric receptor, mapped to UniProt Q9UBL9. ChEMBL maps the protein component as P2X purinoceptor 2. Sequence length is 471 aa.

Mapped IDQ9UBL9
Review nameP2X2/P2X3 heterotrimeric receptor
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

2
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC501,177.0
KI94.0
EC502.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3715500 8.42 Ki 3.802 Preclinical
CHEMBL494161 8.3 IC50 5.012 Preclinical
CHEMBL3727382 8.22 IC50 6.0 Preclinical
CHEMBL3731764 8.15 IC50 7.0 Preclinical
CHEMBL3730477 8.15 IC50 7.0 Preclinical
CHEMBL494161 8.1 Ki 7.943 Preclinical
CHEMBL4583478 8.08 IC50 8.318 Preclinical
CHEMBL3732909 8.05 IC50 9.0 Preclinical
CHEMBL596234 8.05 Ki 9.0 Preclinical
CHEMBL3732768 8.0 IC50 10.0 Preclinical
Distribution

pChEMBL Value Distribution

79
5.0
254
5.5
320
6.0
252
6.5
192
7.0
95
7.5
11
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

GEFAPIXANT
CHEMBL3716057
Approved 2023
Assay Landscape

Assay Landscape

39
Total Assays
466
Tested Compounds
2
Assay Types
Binding — 21 assays, 466 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 12 458 6.3
protein complex format 9 8 6.0
Functional — 18 assays, 229 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 17 229 6.9
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine